99 related articles for article (PubMed ID: 3664483)
1. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).
Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP
Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483
[TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacokinetics of vinorelbine (Navelbine).
Wargin WA; Lucas VS
Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).
Rahmani R; Martin M; Barbet J; Cano JP
Cancer Res; 1984 Dec; 44(12 Pt 1):5609-13. PubMed ID: 6498821
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of navelbine after oral administration in cancer patients.
Zhou XJ; Boré P; Monjanel S; Sahnoun Z; Favre R; Durand A; Rahmani R
Cancer Chemother Pharmacol; 1991; 29(1):66-70. PubMed ID: 1742851
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.
Rahmani R; Guéritte F; Martin M; Just S; Cano JP; Barbet J
Cancer Chemother Pharmacol; 1986; 16(3):223-8. PubMed ID: 3698163
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of vinca alkaloids.
Rahmani R; Zhou XJ
Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
[TBL] [Abstract][Full Text] [Related]
14. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
15. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
[TBL] [Abstract][Full Text] [Related]
16. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
[TBL] [Abstract][Full Text] [Related]
18. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
Winer EP; Chu L; Spicer DV
Semin Oncol; 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9. PubMed ID: 7740337
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
